QuanMedAI
Menu

G8 Geriatric Screening Tool: How It Works, What It Scores, and Why Oncology Uses It

The G8 tool identifies vulnerable older cancer patients in 5 minutes — here is the complete review of its scoring system, 85–87% sensitivity, and how it guides treatment decisions.

By Dr. Elena Marsh, Health Technology Correspondent

Published: November 18, 2026 · 9 min read

Quick Answer

The G8 is an 8-item validated screening questionnaire (scores 0–17) for identifying geriatric vulnerability in older cancer patients. A score ≤14 indicates positive screening and referral for comprehensive geriatric assessment (CGA). Pooled sensitivity is 85–87%, AUC 0.80–0.82. ESMO recommends it for all cancer patients aged 70+ starting treatment. CGA-guided treatment modifications reduce grade 3–4 chemotherapy toxicity by 24% (Lancet Oncology, 2017).

Why Do Older Cancer Patients Need Geriatric Screening?

Cancer disproportionately affects older adults: approximately 60% of new cancer diagnoses in the US occur in patients aged 65 and over, and 70% of cancer-related deaths. As oncology treatment has become more effective, the clinical challenge has shifted — from 'can we treat this cancer?' to 'can this patient tolerate the treatment required?' This question is poorly answered by conventional oncology assessment tools.

ECOG performance status — the standard clinical measure of functional fitness for chemotherapy — has significant limitations in older patients. Two patients with identical ECOG PS 1 scores may have radically different underlying reserve: one may be an active 72-year-old with no comorbidities and normal cognition; another may be a frail 76-year-old with mild cognitive impairment, 4 kg of recent weight loss, and fall history. Standard oncology protocols would treat them identically; geriatric assessment would identify the vulnerability profile that predicts dramatically different treatment tolerance and outcomes.

What Are the G8 Questions and How Are They Scored?

ItemQuestionScore range
AHas food intake declined in the last 3 months?0–2
BWeight loss over last 3 months0–3
CMobility0–2
ENeuropsychological problems (dementia or depression)0–2
FBody mass index (BMI)0–3
HTaking more than 3 medications per day0–1
PSelf-perception of health vs peers0–2
AgeAge ≥80 scores 0; age <80 scores 10–1

Total score: 0–17. Score ≤14 = positive screen (refer for CGA). Score ≥15 = normal screen. Items use the same response format as the Mini Nutritional Assessment (MNA), from which G8 items B, C, E, F, and P are directly derived.

What Evidence Supports G8-Triggered Geriatric Assessment in Oncology?

The clinical rationale for G8 screening is underpinned by several key evidence streams. The validation meta-analysis (JGO 2020, n=5,765) established the tool's psychometric properties: 85–87% sensitivity, 61–65% specificity, AUC 0.80–0.82. The ELCAPA study (Lancet Oncology 2017) provided the highest-quality evidence for clinical impact: 1,100 patients randomised to CGA-guided versus standard treatment showed a 24% reduction in grade 3–4 chemotherapy toxicity in the CGA arm — without compromising response rates. A 2022 systematic review of CGA in surgical oncology (Journal of Geriatric Oncology, 15 RCTs) found that prehabilitation guided by CGA findings reduced postoperative complications by 31% and length of stay by 1.8 days across colorectal, hepatobiliary, and urological cancer surgeries.

Key Sources

  • G8 meta-analysis (n=5,765) — Journal of Geriatric Oncology (2020)
  • ELCAPA study: CGA-guided treatment — Lancet Oncology (2017)
  • ESMO clinical practice guidelines: geriatric oncology (2025)
  • CGA in surgical oncology systematic review — Journal of Geriatric Oncology (2022)
  • G8 development and initial validation — Annals of Oncology (2012)

Frequently Asked Questions

Deep Dive

What Is Precision Medicine?

Our comprehensive guide covers the science, protocols, and tools in detail — with FAQs answered by our research team.

Read the Full Guide →

© 2026 QuanMed - All rights reserved